Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
On his visit to NIPER Mohali, union health minister vreviews biopharma research initiatives and calls for stronger industry collaboration and commercialization focus
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Subscribe To Our Newsletter & Stay Updated
